130048-08-7

Upstream product

• 130954-99-3 ethyl 4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3-quinolinecarboxylate 
• 3800-06-4 2-amino-4'-fluorobenzophenone 
• 105-53-3 diethyl malonate 

Downstream Products

• 130048-09-8 2-chloro-4-(4-fluorophenyl)-3-quinolinemethanol 
• 391681-87-1 methyl 4-(4-fluorophenyl)-2-methoxy-3-quinolinecarboxylate 
• 391681-88-2 ethyl 4-(4-fluorophenyl)-2-methylthio-3-quinolinecarboxylate 
• 943240-96-8 ethyl 5-(4-fluorophenyl)tetrazolo[1,5-a]quinoline-4-carboxylate 
• 391681-93-9 4-(4-fluorophenyl)-2-(N-ethyl-N-methylamino)-3-quinolinecarboxaldehyde 
• 391681-90-6 4-(4-fluorophenyl)-2-methylthio-3-quinolinemethanol 

Relevant academic research and scientific papers

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

A series of quinoline-based 3,5-dihydroxyheptenoic acid derivatives were synthesized from quinolinecarboxylic acid esters by homologation, aldol condensation with ethyl acetoacetate dianion, and reduction of 3-hydroxyketone to evaluate their ability to inhibit the enzyme HMG-CoA reductase in vitro. In agreement with previous literature, a strict structural requirement exists on the external ring, and 4-fluorophenyl is the most active in this system. For the central ring, substitution on positions 6, 7, and 8 of the central quinoline nucleus moderately affected the potency, whereas the alkyl side chain on the 2-position had a more pronounced influence on activity. Among the derivatives, NK-104 (pitavastatin calcium), which has a cyclopropyl group as the alkyl side chain, showed the greatest potency. We found that further modulation and improvement in potency at inhibiting HMG-CoA reductase was obtained by having the optimal substituents flanking the desmethylmevalonic acid portion, that is, 4-fluorophenyl and cyclopropyl, instead of the usual isopropyl group.

Inhibitors of Cholesterol Biosynthesis. 4. trans-6-tetrahydro-4-hydroxy-2H-pyran-2-ones, a Novel Series of HMG-CoA Reductase Inhibitors

A series of substituted quinoline mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and (cholesterol biosynthesis) in vivo.Since previous studies suggested that the 4-(4-fluorophenyl) and 2-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations at position 6 of the quinoline ring.Biological evaluation of a small number of analogues bearing a variety of 6-substituents showed that modification at this position had little effect on potency.Several compounds (8b, 8e, and 11) were identified that showed comparable potency to compaction and mevinolin in both the in vitro and in vivo assays.

6-(2-(2-(SUBSTITUTED AMINO)-3-QUINOLINYL) ETHENYL AND ETHYL) TETRAHYDRO-4-HYDROXYPYRAN-2-ONE INHIBITORS OF CHOLESTEROL BIOSYNTHESIS

Novel 6-[2-[2-(substituted amino)-3-quinolinyl]-ethenyl and ethyl] tetrahydro-4-hydroxypyran-2-ones and/or oxides and the corresponding dihydroxy ring opened acids and esters are described, as well as methods for the preparation and pharmaceutical composi